Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

[1]  A. Lasaridis,et al.  Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. , 2006, American journal of hypertension.

[2]  C. Snehalatha,et al.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.

[3]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[4]  Lawrence A Leiter.  β‐cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes , 2005 .

[5]  C. Semenkovich.  TZDs and diabetes: testing the waters , 2005, Nature Medicine.

[6]  S. Fowler,et al.  Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. , 2005, Diabetes.

[7]  J. Rosenstock,et al.  Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. , 2005, Endocrinology and metabolism clinics of North America.

[8]  H. Krumholz,et al.  Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[9]  K. Kosaka,et al.  Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. , 2005, Diabetes research and clinical practice.

[10]  H. Yki-Järvinen.  Fat in the liver and insulin resistance , 2005, Annals of medicine.

[11]  Lawrence A Leiter.  Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[12]  S. Yusuf,et al.  Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial , 2004, Diabetologia.

[13]  T. Buchanan,et al.  Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. , 2004, The Journal of clinical endocrinology and metabolism.

[14]  U. Boggi,et al.  Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. , 2004, American journal of physiology. Endocrinology and metabolism.

[15]  J. Shaw,et al.  Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study , 2004, International Journal of Obesity.

[16]  S. Grundy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association , 2003, Diabetes care.

[17]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[18]  J. Shaw,et al.  Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[19]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[20]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[21]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[22]  S. Kihara,et al.  Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial. , 2001, Diabetes research and clinical practice.

[23]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[24]  B. Topp,et al.  Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. , 2001, Diabetes.

[25]  任艳,et al.  胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .

[26]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[27]  J. Lachin.  Worst-rank score analysis with informatively missing observations in clinical trials. , 1999, Controlled clinical trials.